TAVR Firm JenaValve Nabs Boston Sci Exec As CEO
This article was originally published in The Gray Sheet
Executive Summary
Victoria Carr-Brendel, who was running Boston Scientific’s Bayer Interventional business, is the new CEO of transcatheter aortic valve company JenaValve. TAVR startup competitor, Direct Flow Medical, also recently hired a new CEO with large-company medtech pedigree.
You may also be interested in...
Direct Flow Taps Lemaitre To Lead Face Off With TAVR Giants
Direct Flow Medical hopes it May 7 appointment of Daniel Lemaitre as CEO will elevate its competitive game against larger players in the transcatheter aortic valve replacement market.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.